Compare Crispr Therapeutics AG (CRSP) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Nomura Holdings Inc — how do they compare? Crispr Therapeutics AG trades at $53.67 (market cap $4.88B), while Nomura Holdings Inc trades at $9.61 (market cap $27.55B). The key difference: Nomura Holdings Inc is far larger — about 5.6× Crispr Therapeutics AG's market cap, and Nomura Holdings Inc pays a 3.4% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Nomura Holdings Inc for 55 Days on average.
| CRSP | NMR | |
|---|---|---|
Market Cap | $4.88B | $27.55B |
Volume | 2,861,747 | 782,470 |
Sector | Health | Financials |
52-Week High | $74.92 | $10.86 |
52-Week Low | $44.34 | $6.73 |
Typical Hold Time | 77 Days | 55 Days |
Enterprise Value | $3.30B | $38.54T |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
Nomura Holdings (NMR) trades at $9.57, showing modest daily gains of 0.42%. The stock presents a mixed technical picture with bearish moving averages but oversold RSI readings. Fundamentally, NMR demonstrates strong profitability with 20.4% net margins and attractive valuation metrics including a P/E of 11.33 and P/B of 1.15. Recent earnings show volatility with two misses and one beat in the last four quarters. The company maintains robust revenue growth, reaching $1.66 trillion in 2025 with expanding profit margins.
NMR offers value investment appeal with reasonable valuations and solid profitability, though technical weakness and inconsistent earnings performance present near-term challenges. The stock's current oversold condition combined with strong fundamental metrics suggests potential for recovery, but investors should monitor earnings consistency and debt levels that have been trending upward. Analyst sentiment remains cautiously optimistic with a buy rating consensus despite recent technical pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
